Physician profile
Chandrahasa Annem
NPI 1801175559
$811.30
in general payments reported to CMS, 2019-2025
10 companies · $205 in 2025
The $205 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $69.65 · 2020: $29.11 · 2021: $227 · 2022: $91.45 · 2023: $104 · 2024: $84.91 · 2025: $205.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $322 · Education: $72.45.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $321.50 |
| Education | $72.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $230.73 | 2019-2025 | Tavneos, Krystexxa, Otezla |
| Ucb, INC. | $214.28 | 2020-2025 | Bimzelx, Cimzia |
| Abbvie INC. | $106.28 | 2024-2025 | |
| Glaxosmithkline, LLC. | $76.51 | 2022-2025 | Shingrix, Arexvy |
| Pfizer INC. | $58.49 | 2019-2021 | |
| Genentech USA, INC. | $34.47 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $33.61 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $20.77 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $18.71 | 2021 | |
| Actelion Pharmaceuticals US, INC. | $17.45 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chandrahasa Annem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.